This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Domanski, P. J.
Right arrow Articles by Patti, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Domanski, P. J.
Right arrow Articles by Patti, J. M.

 Previous Article  |  Next Article 

Infection and Immunity, August 2005, p. 5229-5232, Vol. 73, No. 8
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.8.5229-5232.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Characterization of a Humanized Monoclonal Antibody Recognizing Clumping Factor A Expressed by Staphylococcus aureus

Paul J. Domanski,1 Pratiksha R. Patel,1 Arnold S. Bayer,2 Li Zhang,1 Andrea E. Hall,1 Peter J. Syribeys,1 Elena L. Gorovits,1 Dawn Bryant,1 John H. Vernachio,1 Jeff T. Hutchins,1 and Joseph M. Patti1*

Inhibitex, Inc., Alpharetta, Georgia,1 LA Biomedical Research, Torrance, California2

Received 4 October 2004/ Returned for modification 1 December 2004/ Accepted 14 March 2005

We report the humanization and characterization of monoclonal antibody (MAb) T1-2 or tefibazumab, a monoclonal antibody that recognizes clumping factor A expressed on the surface of Staphylococcus aureus. We demonstrate that the binding kinetics of MAb T1-2 is indistinguishable compared to that of its murine parent. Furthermore, MAb T1-2 is shown to enhance the opsonophagocytic uptake of ClfA-coated latex beads, protect against an intravenous challenge in a prophylactic model of rabbit infective endocarditis, and enhance the efficacy of vancomycin therapy in a therapeutic model of established infective endocarditis.

* Corresponding author. Mailing address: Inhibitex, Inc., 9005 Westside Parkway, Suite 400, Alpharetta, GA 30004. Phone: (678) 746-1144. Fax: (678) 746-0624. E-mail: jpatti{at}inhibitex.com.

Editor: F. C. Fang

Infection and Immunity, August 2005, p. 5229-5232, Vol. 73, No. 8
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.8.5229-5232.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Baer, M., Sawa, T., Flynn, P., Luehrsen, K., Martinez, D., Wiener-Kronish, J. P., Yarranton, G., Bebbington, C. (2009). An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity. Infect. Immun. 77: 1083-1090 [Abstract] [Full Text]  
  • Tuchscherr, L. P. N., Buzzola, F. R., Alvarez, L. P., Lee, J. C., Sordelli, D. O. (2008). Antibodies to Capsular Polysaccharide and Clumping Factor A Prevent Mastitis and the Emergence of Unencapsulated and Small-Colony Variants of Staphylococcus aureus in Mice. Infect. Immun. 76: 5738-5744 [Abstract] [Full Text]  
  • Bekeredjian-Ding, I., Inamura, S., Giese, T., Moll, H., Endres, S., Sing, A., Zahringer, U., Hartmann, G. (2007). Staphylococcus aureus Protein A Triggers T Cell-Independent B Cell Proliferation by Sensitizing B Cells for TLR2 Ligands. J. Immunol. 178: 2803-2812 [Abstract] [Full Text]  
  • Hetherington, S., Texter, M., Wenzel, E., Patti, J. M., Reynolds, L., Shamp, T., Swan, S. (2006). Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.. Antimicrob. Agents Chemother. 50: 3499-3500 [Abstract] [Full Text]  
  • Weems, J. J. Jr., Steinberg, J. P., Filler, S., Baddley, J. W., Corey, G. R., Sampathkumar, P., Winston, L., John, J. F., Kubin, C. J., Talwani, R., Moore, T., Patti, J. M., Hetherington, S., Texter, M., Wenzel, E., Kelley, V. A., Fowler, V. G. Jr. (2006). Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus Bacteremia.. Antimicrob. Agents Chemother. 50: 2751-2755 [Abstract] [Full Text]  
  • Pourmand, M. R., Clarke, S. R., Schuman, R. F., Mond, J. J., Foster, S. J. (2006). Identification of Antigenic Components of Staphylococcus epidermidis Expressed during Human Infection.. Infect. Immun. 74: 4644-4654 [Abstract] [Full Text]  
  • Kelly-Quintos, C., Cavacini, L. A., Posner, M. R., Goldmann, D., Pier, G. B. (2006). Characterization of the Opsonic and Protective Activity against Staphylococcus aureus of Fully Human Monoclonal Antibodies Specific for the Bacterial Surface Polysaccharide Poly-N-Acetylglucosamine.. Infect. Immun. 74: 2742-2750 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»